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Introduction
Osteosarcoma (OS) is the most common primary malignant
bone cancer in children and adolescents, characterized by the
presence of spindle-like tumor cells which produce immature bone
or osteoid. The overall incidence is three patients/million/year
with the median peak at the age of 16 [1]. OS has a high
propensity for metastasis to the lung and bones. Twenty percent of
the patients have detectable metastases already at the time of
diagnosis and eighty percent of the patients who initially present
with localized disease subsequently develop metastases [2,3].
Significant clinical improvements over the past several decades
through the use of combined chemotherapy and surgery have led
to a dramatic increase in the survival of patients with localized
disease. However, patients with metastatic or recurrent disease
continue to have a very poor prognosis, with ,20% long term
survival [3]. Therefore, it is of great importance to elucidate the
molecular mechanisms of OS metastasis. A detailed understanding
of these mechanisms will in the future guide the design of novel
treatment strategies and the development of corresponding
metastasis suppressive compounds that will finally help to improve
the survival of OS patients.
Previous studies revealed evidence for important functions of
CD44 gene products during metastatic spread of numerous types
of tumors [4] and respective proteins were therefore considered as
targets for anti-metastatic treatment. Moreover, several reports
have described prognostic power of CD44 gene products in
different cancer types [5,6,7]. CD44 gene products are trans-
membrane proteoglycans, which act as cell-cell and cell-matrix
adhesion molecules and principle receptors of hyaluronan (HA)
[8]. They exist as multiple isoforms that are generated from a
single primary gene transcript by alternative splicing combined
with varying posttranslational glycosylation [9]. As a result, the
extracellular domains of CD44 isoforms consist of variable regions,
encoded by variant exons, and are glycosylated to different
extents. The standard isoform CD44s, also described as CD44H
(hematopoietic), is the smallest CD44 gene product and does not
contain any of the variable extracellular regions encoded by the
variant exons. The structural differences in the extracellular
domains of the CD44 isoforms largely define a wide range of
biological functions in development, inflammation, haematopoie-
sis, wound healing, immune response and cancer [4]. In tumor
biology, evidence has accumulated that metastasis in different
types of cancer is directly or inversely related to the expression of
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CD44 gene products, depending on the expression pattern of
CD44 isoforms and on the organ of origin. Several studies have
shown up-regulated expression of CD44 isoforms in many human
tumors, including gastric cancer, pancreatic cancer, lung and renal
cell cancer [6,10,11,12]. Some reports point to important
functions of CD44s in tumor progression [13]. However, in other
tumor types, such as neuroblastoma and prostate cancer, the
absence of CD44 gene products correlated with poor prognosis
[7,14]. In prostate carcinoma cells, CD44 was even considered as
a metastasis-suppressor gene [4,15]. Thus, the functions of CD44
gene products in tumor biology are controversially discussed.
Little is known on potential functions of CD44 gene products in
OS pathophysiology and in OS metastasis in particular. Two
immunohistochemical studies of OS tissue specimens revealed
discrepant results. Kim et al. reported that overexpression of the
CD44v5 isoform (CD44s with an additional amino acid sequence
in the extracellular domain encoded by variant exon 5) in tumor
tissue correlated significantly with metastatic disease and, conse-
quently, lower survival rates of the patients [16]. In the tumor
samples analyzed by Kuryu et al., on the other hand, a poor
prognosis for OS patients correlated with overexpression of the
CD44 isoforms that contain in the extracellular domain the amino
acid sequence encoded by variant exon 6 (CD44v6) [17]. In both
studies, immunostaining with CD44 antibodies detecting all
expressed CD44 isoforms in tumor tissue together (pan CD44
antibodies) was not a prognostic indicator.
As outlined before, HA is the principle ligand of CD44 gene
products. In OS, a few studies with established OS cell lines
revealed evidence for a tumor promoting effect of HA. Hosono et
al. showed that in vitro and in vivo tumorigenic properties of the OS
cell lines MG63 and LM8 were inhibited by HA oligosaccharides
that perturbed the HA-rich pericellular matrix [18]. A study
performed by Nishida et al. showed diminished retention of HA
and inhibition of tumorigenicity of MG63 OS cells upon antisense
inhibition of HA synthase (HAS)-2 [19]. HAS-3-derived HA
enhanced the cellular properties required for OS metastasis, such
as proliferation, invasion and degradation of extracellular matrix in
vitro [20].
The controversial discussions on the relevance of CD44 gene
products in cancer biology in general and the limited knowledge
on their biological functions in OS and metastasis in particular
prompted us to perform the here reported CD44 silencing study in
an intratibial OS xenograft model in SCID mice that makes use of
the human highly metastatic 143-B cell line and reproduces the
human disease with metastasis to the lung. The expression of
CD44 gene products, predominantly CD44s, in the 143-B OS
cell line, found to be representative for the CD44 isoform
expression pattern in other OS cell lines, was stably downregulated
by retroviral expression of shRNA. The effects of this manipula-
tion in 143-B cells on the metastatic behavior in vitro and on
intratibial tumor growth and lung metastasis in SCID mice were
investigated.
Materials and Methods
Cell culture and transduction
Human 143-B OS cells (CRL-8303) were obtained from
American Type Culture Collection (ATCC, Rockville, MD).
The cells were cultured in DMEM (4.5 g/l glucose)/HamF12 (1:1)
medium (Invitrogen; Carlsbad, CA), supplemented with 10%
heat-inactivated FCS (GIBCO, Basel, Switzerland), at 37uC in a
humidified atmosphere of 5% CO2/95% air. CD44 expression
was stably silenced by retroviral expression of shRNA in 143-B
cells that were transduced with a LacZ gene for tumor cell
identification by X-gal staining in mouse tissues [21]. Retroviral
constructs in the pSirenRetroQ vector (Clontech; Paolo Alto, CA)
coding for CD44 transcript-targeting shRNA (shCD44) and for
non-targeting control shRNA (Ctrl shRNA) were kindly provided
by Prof. Ivan Stamenkovic (Lausanne, Switzerland) [22]. Retro-
viral particles containing shCD44 or Ctrl shRNA constructs or the
empty pSirenRetroQ vector (EV) with a puromycin resistance
gene were produced in HEK293-T cells according to a protocol
reported by Arlt et al. [23]. LacZ-transduced 143-B cells were
infected with retroviruses by incubation for 48 h in virus-
containing medium supplemented with 8 mg/ml polybrene.
Retrovirus infected cells were subsequently selected and main-
tained in cell culture medium containing 2 mg/ml puromycin
(Invitrogen). The selection revealed LacZ-expressing 143-B EV,
143-B shCD44 and 143-B Ctrl shRNA sublines. Prior to animal
experiments, 143-B shCD44 cells were further enriched by
incubation in tissue culture medium on HA-coated plates
(100 mg/cm2; Sigma Aldrich, St. Luis, MO) at 37uC for 10 min
that removed cells with inefficiently silenced CD44 expression.
Non-adherent 143-B shCD44 cells in the supernatant were
collected and used for animal experiments.
Immunocytochemistry
Cells were allowed to grow to subconfluence on glass
microscope cover slips in 24-well plates. After washing with
PBS, the cells were fixed with 4% formalin in PBS at room
temperature (RT) for 20 min. Permeabilization and non-specific
antibody binding to cell monolayers were achieved by preincuba-
tion at RT for 30 min in DMEM/F12 (1:1) medium containing
0.1% BSA and 0.1% saponin (blocking medium). The cells
were then incubated at RT for 2 h with the primary pan
CD44 antibody (Hermes3, kindly provided by Dr. Sirpa Jalkanen,
Turku, Finland; 2 mg/ml in blocking medium). After extensive
washing with blocking medium, secondary Alexa Fluor 546-
labeled antibodies to mouse IgG (Invitrogen) at 1:200 final
dilution were added and the cells incubated in the dark for 30 min.
F-actin was stained with Alexa Fluor 488–labeled phalloidin
(Invitrogen) and cell nuclei were visualized with DAPI. The
coverslips were then washed with PBS and dipped in H2O and
then mounted in Immomount (ThermoScientific; Waltham, MA).
Fluorescence was examined with a Nikon Eclipse E600 micro-
scope equipped with appropriate filter blocks (Nikon Corporation,
Tokyo, Japan).
Western blot analysis
Cells were lysed by incubation at 4uC for 1 h on a moving
carrousel in lysis buffer consisting of 50 mM Tris/HCl (pH 7.5),
150 mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% sodium
dodecyl sulfate (SDS), 1 mM dithiothreitol (DTT), 1 mM
phenylmethylsulphonyl fluoride (PMSF) and 10 mg/ml aprotinin.
Cellular debris were pelleted by centrifugation at 160606g and
4uC for 20 min. Equal amounts of proteins in supernatants were
separated by 8% SDS-PAGE and then blotted onto Hybond-ECL
membranes (GE Healthcare, UK). CD44 and b-actin were
detected with mouse monoclonal Hermes3 antibodies (1 mg/ml)
and antibodies to b-actin (Chemicon, Dietikon, Switzerland, final
dilution 1:10000), respectively. HRP-conjugated secondary anti-
bodies were purchased from Santa Cruz Biotechnologies. Perox-
idase activity was visualized with Immobilon chemoluminescence
substrate (Millipore, Billerica, MA) and a VersaDocTMImaging
System (Bio-Rad; Hercules, CA).
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Adhesion assay
Adhesion assays were performed in 96-well plates. The wells
were coated with 100 ml per well of 1 mg/ml high molecular
weight HA diluted in PBS (333 mg/cm2 of HMW-HA; Sigma-
Aldrich) at 4uC over night. They were then washed with PBS and
blocked with heat-denatured (HD) 1% BSA in PBS at RT for 1 h.
Non-coated wells or wells coated with HD-BSA alone were used as
controls. Cells grown to subconfluence were detached with
accutase (Sigma-Aldrich) and 104 cells per well were seeded in
triplicates and allowed to adhere at 37uC for 30 min. Non-
adherent cells were removed by washing and adherent cells were
then fixed with 10% formalin in PBS at RT for 15 min and
subsequently stained with 0.05% crystal violet in H2O at RT for
15 min. Photos of an area of 3.6 mm2 were taken with an
AxioCam MRm camera connected to the Zeiss Observer.Z1
inverted microscope adjusted to 46magnification. The number of
adherent cells was determined with ImageJ software. The
percentage of adherent cells was calculated from the total number
of adherent cells per well divided by the total number of seeded
cells and multiplied by 100. The percentage of adherent 143-B
Ctrl shRNA and 143-B shCD44 cells was normalized to the
percentage of adherent 143B EV cells set to 100%. The data of
three independent experiments are presented.
Migration assay
Transwell migration assays were performed as recently reported
[23]. Briefly, 52106103 cells were allowed to migrate at 37uC for
6 h through 8 mm porous polycarbonate filters of cell culture
inserts (Becton Dickinson, San Jose, CA) fitting into 24-well plates.
Cells remaining on the upper side of the filter insert were
considered as non-migrating cells and removed by wiping with a
cotton swab. Migrated cells on the lower side of the filters were
fixed with 10% formalin in PBS, permeabilized with 50 mM
digitonin (Calbiochem; Switzerland) and stained with 300 nM
Picogreen in PBS (Invitrogen) at RT for 15 min. Three randomly
selected filter areas of 0.58 mm2 per insert (two filters per cell line)
were photographed with an AxioCam MRm camera connected to
the Zeiss Observer.Z1 inverted microscope equipped with an
appropriate filter block for blue excitation and set to 106
magnification. The number of cells that migrated to the lower
side of the polycarbonate filters was determined with ImageJ
software. The results are presented as described for the adhesion
assay. The experiments were carried out at least three times.
Proliferation assay
Subconfluent, logarithmically growing cells were trypsinized
and 56104 cells in 2.5 ml of cell culture medium were seeded in
triplicates in 12.5 cm2 flasks and allowed to grow for between 1
and 5 days and collected at one-day intervals by trypsinization.
The cell number/flask was determined by counting aliquots of
harvested cells in a Neubauer chamber. The equation N=No e
kt
was used to calculate the doubling time during logarithmic growth.
Soft agar colony formation assay
Experiments were carried out in 6-well plates. A bottom agar
layer in individual wells was generated with 1.5 ml of 0.5% DNA
grade agarose (Promega, Madison, WI) in cell culture medium.
The plates were kept at 4uC until use. 26104 cells in 1.5 ml of
0.35% agarose in cell culture medium were seeded per well in
triplicates on top of the bottom agar layer. The cells were cultured
at 37uC for 24 h before 2 ml per well of cell culture medium with
penicillin/streptomycin/amphotericin B (PSA, 1:100; Invitrogen)
were added. The medium was replaced every 3 days and the cells
were cultured for 14 days. Cell colonies were then stained with
2 ml 0.005% crystal violet at 4uC overnight. Three randomly
selected areas per well were photographed with an AxioCam
MRm camera connected to a Zeiss Observer.Z1 inverted
microscope set to 46 magnification. ImageJ software was used
to determine the number and the size distribution of colonies. The
mean number of colonies per well formed by the individual
manipulated cell lines was calculated and normalized to that of
143-B EV cells set to 100%. The experiments were repeated four
times in triplicates.
Intratibial xenograft OS mouse model
Eight week old SCID/CB17 immunocompromised mice were
obtained from Charles River Laboratories (Sulzfeld, Germany) at
least 14 days before the start of the experiment. The animal
experiments were approved (License Number 129/2009) by the
Ethics Committee of the Veterinary Office of the Kanton Zu¨rich
and were conducted in accordance with the guidelines of the
‘‘Schweizer Bundesamt fu¨r Veterina¨rwesen’’. On day 0 of the
experiments, 26105 of 143-B cells (engineered as described) in
10 ml of PBS/0.05% EDTA containing Matrigel (Becton-
Dickinson; Franklin Lake, NJ) were injected intratibially. After
the injections, the health condition of the mice was closely
monitored. Tumor development was examined weekly by X-ray
with an MX-20 DC Digital Radiography System (Faxitron X-Ray
Corporation, Lincolnshire, IL) and by caliper measurements of the
length and the width of the tumor leg from which the tumor
volume was calculated with the formula V= length6width2/2.
The mice were sacrificed 21 days after tumor cell injection and in
situ lung perfusion was performed as described [23]. Organs
collected at sacrifice were fixed in 2% formaldehyde at RT for
30 min, washed three times with PBS and LacZ gene expressing
tumor cells were stained with 5-bromo-4-chloro-3-indolyl-b-D-
galactoside (X-Gal) staining solution at 37uC for at least 3 h as
described [24,25]. The indigo-blue stained metastases on the lung
surface were counted under the microscope. The animal
experiments were carried out three times. The data of a
representative experiment are shown.
Immunohistochemistry
Tumors and lungs previously fixed in 4% formaldehyde were
dehydrated through serial incubation in 70%, 96%, 100% ethanol
and xylene and then embedded in paraffin. Sections of 6 mm were
mounted onto slides, deparaffinized and rehydrated and then
heated in 0.1 M citrate buffer (pH 5.8) for antigen retrieval.
Endogenous peroxidase was inactivated by incubation of the tissue
sections in 3% H2O2 at RT for 10 min. Non-specific binding of
antibodies to tissue sections was blocked by incubation at RT for
1 h in Tris buffered saline (TBS; 50 mM Tris, 150 mM NaCl,
pH 7.4) that contained 10% goat serum (Vector Laboratories;
Burlingame, CA) and 0.1% Tween (Sigma Aldrich). Primary
Hermes3 CD44 antibodies (2 mg/ml in blocking solution), and
antibodies to merlin NF2 (Santa Cruz Biotechnologies; 4 mg/ml)
and to Ki67 (Abcam; Cambridge, UK; 4 mg/ml) were then
applied and the slides incubated at RT for 1 h. After washing with
TBS, the slides were incubated with secondary biotinylated goat
anti-mouse IgG (Vector; 1:200) at RT for 1 h. Slides incubated
with secondary antibody alone served as negative controls. After
another wash with TBS, the sections were incubated with avidin-
conjugated peroxidase (ABC kit; Vector Laboratories) at RT in the
dark for 30 min, washed again with TBS, and then incubated with
the peroxidase substrate AEC (Dako; Glostrup, Denmark) for
staining. Finally, the slides were briefly counterstained with
hematoxylin. Recombinant mouse CD44 Fc chimera (R&D
CD44 Silencing Promotes Osteosarcoma Metastasis
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Systems, Minneapolis, MN; 10 mg/ml) were used for the staining
of HA in tissue sections with the standard protocol for
immunostaining excluding antigen retrieval. For negative controls,
tissue sections were treated with hyaluronidase (200 U/ml; Sigma
Aldrich) at 37uC overnight prior to HA staining, or the CD44 Fc
chimera were preincubated with HA (1 mg/ml; Sigma Aldrich)
before application to the slides.
Statistical analysis
Differences between means were analyzed by the Student t-test
and p,0.05 was considered significant. The results are presented
as means 6 SEM.
Results
shRNA-mediated silencing of the CD44 gene in the
human metastatic 143-B OS cell line diminishes in vitro
metastatic properties
An analysis in 143-B cells of the products derived from the
CD44 gene revealed predominant expression of the standard
CD44s isoform, a finding that was consistent with observations in
other established as well as primary human OS cell lines (not
shown). Based on the previously reported malignant phenotype of
143-B cells in vivo, which, upon intratibial injection, nicely
reproduced the human disease with primary osteolytic bone lesion
that metastasize to the lung [26], 143-B cells stably expressing a
Figure 1. shRNA-mediated downregulation of CD44 expression in 143-B OS cells. (A) Western blot analysis with the panCD44 Hermes3
antibody of total CD44 gene-derived protein products in extracts of 143-B EV (EV), 143-B Ctrl shRNA (Ctrl shRNA) or 143-B shCD44 (shCD44) cells. b-
Actin was used as a loading control. (B) Cell immunostaining of CD44 (red) in saponin permeabilized 143-B EV (EV), 143-B Ctrl shRNA (Ctrl shRNA) or
143-B shCD44 (shCD44) cells. Actin filaments (green) and cell nuclei (blue) were visualized with Alexa Fluor 488-labeled phalloidin and DAPI,
respectively. Bars, 100 mm.
doi:10.1371/journal.pone.0060329.g001
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LacZ gene were used to study the biological relevance of CD44
molecules in OS aggressiveness. Retroviral transduction of 143-B
cells with a vector for stable expression of CD44 gene transcript-
targeting shRNA revealed effective downregulation of CD44 gene-
derived protein products in cell extracts and in the cell monolayers
visualized by immunocytochemistry (Figure 1A and B). This was
not observed in 143-B cells transduced with empty-vector
retroviruses or with viruses producing non-specific control shRNA.
Staining of actin filaments, on the other hand, clearly demon-
strated that morphological features of the three cell lines were not
affected by the described manipulations. This silencing of the
CD44 gene in 143-B cells reduced their capacity to adhere to HA
by 736 7.5% (p,0.02) compared to that observed with 143-B EV
cells (Figure 2A). The adhesion of 143-B Ctrl shRNA cells with
maintained CD44 expression, on the other hand, was indistin-
guishable from that of 143-B EV cells. Similarly, the CD44
silencing observed in 143-B shCD44 cells reduced the migration
rate by 57 6 4.2% (p,0.0001) compared to that of 143-B EV
cells, which was also indistinguishable from that of 143-B Ctrl
shRNA cells (Figure 2B). Interestingly, CD44 silencing had no
effect on proliferation of 143-B cells in 2D culture (Figure 2C). Cell
cycle distribution assessed by propidium iodide staining followed
by flow cytometry was identical in the respective cell line
populations (Figure S1). The number of 143-B shCD44 cell
colonies growing anchorage-independent in soft agar, on the other
hand, was 28 6 6% (p,0.02) lower than that of 143-B EV cells,
which was comparable to that of 143-B Ctrl shRNA cells
(Figure 2D). The size of growing colonies of the three cell lines
in soft agar did not differ (not shown).
CD44 silencing in 143-B OS cells enhances their malignancy in
SCID mice
The results of the in vitro characterization of the malignant
properties of 143-B shCD44, - Ctrl shRNA and - EV cells
suggested that stable shRNA-mediated silencing of the CD44 gene
in 143-B cells might also affect the development in vivo of intratibial
143-B cell-derived primary tumors and lung metastasis. Three
groups of SCID mice were therefore intratibially injected with
143-B shCD44, - Ctrl shRNA or - EV cells, respectively. Fourteen
Figure 2. Effects of CD44 silencing on in-vitromalignant properties of 143-B OS cells. (A) Adhesion to HA (n = 3), (B) trans-filter migration
(n = 6), (C) proliferation (n = 3) and (D) anchorage-independent growth (n = 4) of 143-B EV (EV), 143-B Ctrl shRNA (Ctrl shRNA) or 143-B shCD44
(shCD44) cells. Values represent the mean 6 SEM; *, p,0.05.
doi:10.1371/journal.pone.0060329.g002
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days after tumor cell injection, similar osteolytic lesions, charac-
teristic for 143-B cell-derived tumors, were recognized by X-ray in
all three groups of mice (Figure 3A). Somehow unexpectedly,
caliper measurements of the volume of the tumor legs over time
revealed growth of intratibial primary tumors to a significantly
(p,0.001) larger final size at sacrifice on experimental day 20 in
mice injected with 143-B shCD44 cells (108 6 14 mm3, n= 9)
than in animals that received 143-B EV cells (39 6 6 mm3, n= 9)
(Figure 3B). The mean size of tumors developing in mice injected
with 143-B Ctrl shRNA cells (65 6 25 mm3, n = 6) was
intermediate, but not significantly different from that in mice
injected with 143-B shCD44 or with 143-B EV cells, most
probably due to the fact that Ctrl shRNA group consisted of only 6
animals that exhibited greater heterogeneity in tumor size than the
other experimental groups. Two of the 6 mice of 143-B Ctrl group,
in particular, developed remarkably larger primary tumors than
the other 4 mice of this group and all mice in the 143-B EV group
that were similar in size. Interestingly, beside the described larger
size of 143-B shCD44 compared to 143-B EV and 143-B Ctrl
shRNA cell-derived primary tumors, the mean number of
metastatic lesions on lung surfaces at sacrifice, detected by X-gal
staining, were also found significantly increased 2-fold (p,0.05)
and 2.4-fold (p,0.05) in mice with 143-B shCD44 cell-derived
tumors compared the numbers counted on the lungs of animals
injected with 143-B EV or 143-B Ctrl shRNA cells, respectively
(Figure 3C, D).
In view of the discrepant malignant properties of 143-B shCD44
cells in vitro and in vivo, we assessed the expression of immunore-
active CD44 by immunohistochemistry with Hermes3 antibodies
in primary tumor tissue and lung metastases derived from 143-B
shCD44 cells and compared it with 143-B EV and 143-B Ctrl
shRNA cell-derived tumors. This analysis demonstrated that
Figure 3. Effects of CD44 silencing on intratibial primary tumor growth and lung metastasis of 143-B OS cells in SCID mice. (A)
Primary tumor development over time monitored by X-ray or (B) by tumor leg volume measurement at indicated time points in mice intratibially
injected with 143-B EV (EV) (n = 9), 143-B Ctrl shRNA (Ctrl shRNA) (n = 6) or 143-B shCD44 (shCD44) (n = 9) cells. (C) Representative images and (D)
quantification of X-gal stained (blue) metastases on whole-mounts of lungs collected from mice intratibially injected with 143-B EV (EV) (n = 9), 143-B
Ctrl shRNA (Ctrl shRNA) (n = 6) or 143-B shCD44 (shCD44) (n = 9) cells. Values are expressed as mean 6 SEM; *, p,0.05.
doi:10.1371/journal.pone.0060329.g003
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CD44 silencing was maintained in vivo in 143-B shCD44 cells
(Figure 4C and I). The content of HA in the extracellular matrix of
primary tumors, on the other hand, was indistinguishable in 143-B
shCD44, -EV and -Ctrl shRNA cell-derived tumors, indicating
that the levels of expression of CD44 gene products in 143-B cells
did not affect extracellular HA deposition (Figure 4D-F).
Interestingly, nuclear Ki67 immunostaining of proliferating tumor
cells on primary tumor and lung paraffin sections showed a specific
structure of primary tumors and lung metastases in mice bearing
tumors depleted of CD44. 143-B shCD44 cells appeared to be in
much looser contact in primary tumors and metastases than 143-B
EV and 143-B Ctrl shRNA cells that formed remarkably denser
malignant tissue than 143-B shCD44 cells (Figure 5A-F). The
discrepant effects of CD44 silencing in 143-B cells observed in vitro
and in vivo suggested different responses to this manipulation of
cells in culture and in the living animal. Merlin, known to have
tumor suppressor activity upon binding to the cytoplasmic domain
of HA-interacting CD44 and thereby conferring cell growth arrest
by contact inhibition [27], was considered as a candidate molecule
contributing to the regulation of 143-B cell aggressiveness.
Immunohistochemistry on intratibial primary tumor and lung
paraffin sections indeed showed remarkably lower merlin protein
levels in 143-B shCD44 than in 143-B EV and 143-B Ctrl shRNA
cell-derived tumors and pulmonary metastases (Figure 5). Such
differences in merlin protein levels in the three manipulated cell
lines were not observed in vitro (not shown).
Discussion
Only a few studies addressed so far the biological relevance of
CD44 expression in OS progression and metastasis and the results
are controversial. One study did not find a correlation between
CD44 protein expression and overall survival of OS patients [28]
and in a second study, OS patients with high CD44 mRNA
expression levels in primary tumor tissue were found to be more
prone to have metastases than those with low expression [29].
Moreover, expression of distinctive CD44 isoforms was found to
be correlated with unfavorable prognosis [16,17].
Here, we aimed at determining the role of CD44 in the human
143-B OS cell line with metastatic activity, which has robust
endogenous CD44 expression and was selected as representative
for OS. Therefore, we silenced the expression of CD44 gene
products in 143-B cells and studied its impact in vitro and in vivo in
an intratibial xenograft OS model in SCID mice. Interestingly, we
Figure 4. Ex-vivo immunohistochemical analysis of shRNAmediated CD44 silencing in 143-B-lacZ OS cell-derived intratibial primary
tumors and pulmonary metastases. Robust expression of immunoreactive CD44 observed in primary tumor (PT) tissue and pulmonary
metastases (PM) derived from 143-B EV (EV) (A,G) and 143-B Ctrl shRNA (Ctrl shRNA) cells (B,H) was found suppressed in tumor tissue (C) and lung
metastases (I) derived from 143-B shCD44 (shCD44) cells. Immunohistochemically detectable HA in PT (panels D-F) was not affected by CD44
silencing. The figure shows images of representative 6 mm paraffin sections with cell nuclei counterstained with hematoxylin. Bars, 100 mm.
doi:10.1371/journal.pone.0060329.g004
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obtained discrepant findings in vitro and in vivo. In vitro, stable
shRNA-mediated CD44 knock-down significantly suppressed cell
migration and growth in soft agar, implying that CD44 may
contribute to the increased metastatic properties of 143-B cells.
However, upon intratibial injection into SCID mice, 143-B cells
with reduced CD44 expression even enhanced the malignant
phenotype when compared to control cells. Mice bearing shCD44
xenografts developed larger primary tumors and had significantly
increased number of pulmonary metastases when compared to
those in control animals. In contrast to our in vitro data,
experiments in vivo using the orthotopic xenograft mouse model
identified CD44 as a metastasis suppressor gene in 143-B cells.
A plausible explanation for the enhanced metastatic activity in
cells depleted of CD44 is their decreased adhesion to HA-rich
extracellular matrices within primary tumors, consistent with the
reduced adhesion to HA that we observed in vitro. Furthermore,
histology of tumor tissue revealed a low adhesive structure of
143-B shCD44 cells with wide intercellular gaps, as opposed to
control transduced cells. The changes in adhesive properties of
shCD44 cells may also have facilitated their mobility and enabled
expansion and dissemination beyond the primary tumor site,
ultimately leading to elevated metastatic potential. A study
performed by Lopez et al. is in good agreement with our concept,
in which they report that CD44 loss has a metastasis-promoting
effect in a mouse model of spontaneously metastasizing breast
cancer [30]. Moreover, the authors show that CD44/HA
interactions inhibit invasion in a three-dimensional in vitro invasion
assay, suggesting that CD44 engagement with HA is protective
against metastasis. Another explanation for the elevated malignant
phenotype in 143-B cells with silenced CD44 is the observed loss
of merlin protein expression in vivo in these cells. Merlin is encoded
by neurofibromatosis type 2 (NF2) gene and mutations and
deletions of merlin underlie NF2 familial cancer syndrome,
characterized by development of schwannomas, meningiomas
and ependymomas [31]. As mutations of NF2 were also detected
in other cancer types, it is considered as a tumor suppressor gene
in a wide variety of tumor cells. Merlin is a multifunctional protein
that regulates cell shape, proliferation, survival, motility and
Figure 5. CD44 silencing in 143-B OS cells reduced the density of proliferating cells in intratibial primary tumors and decreased the
content of the tumor suppressor merlin in primary tumors and pulmonary metastases to immunohistochemically nearly
undetectable levels. Representative images of 6 mm paraffin sections of primary tumor (PT) (panels A-C and G-I) and of lung tissue with pulmonary
metastases (PM) (panels D-F and J-L) stained for the proliferation marker Ki67 (panels A-F) and for merlin (panels G-L). Tissues were collected at
sacrifice from SCID mice intratibially injected with 143-B EV (EV), 143-B Ctrl shRNA (Ctrl shRNA) or 143-B shCD44 (shCD44) cells. Bars, 100 mm.
doi:10.1371/journal.pone.0060329.g005
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invasion. Interestingly, mice heterozygous for a mutation at the
NF2 locus (Nf2+/-) are cancer prone, and develop a wide
spectrum of tumors, most frequently OS, that display strikingly
high metastatic proclivity, unlike the benign tumors in human
patients with NF2 syndrome [32]. This study provided experi-
mental support for the association of NF2 loss and elevated
metastatic potential. Conversely to the observations in mice, in
human OS patient samples NF2 mutations could not be found,
whereas merlin protein could be detected, implicating the
apparent differences between the mouse and human OS
tumorigenesis [33]. Nevertheless, as merlin functions as a tumor
and metastasis suppressor, accelerated tumor growth and
enhanced ability to form metastases seen in the intratibial OS
mouse model presented here may be the consequence of loss of
merlin’s expression in 143-B shCD44 cells. In breast cancer, in
which mutations are absent as in OS, the stability of merlin
mRNA was found unaltered [34]. A recent report by Morrow et
al. showed that the loss of merlin protein observed in breast cancer
tissues occurs without any change at the transcript level and is a
result of proteasomal degradation induced by osteopontin initiated
Akt-mediated phosphorylation of merlin [35]. Mechanisms
underlying merlin loss in OS cells need yet to be elucidated.
Additionally, merlin has been reported to reverse the Ras-induced
malignant phenotype [36]. Given the fact that 143-B cells were
generated through Ki-Ras transformation [37], we suggest that
Ras-driven metastatic behavior is even more pronounced upon
loss of merlin protein expression in vivo. Therefore, we cannot
exclude the possibility of a cell-type specific effect of CD44 down-
regulation on tumor and metastasis formation. However, CD44
may act as a metastasis suppressor by regulating merlin expression
or function in a subset of OS where Ras signaling is involved.
RHAMM, another HA binding protein that is expressed in 143-B
cells (not shown), might be an additional player in our model.
Nedvetzki et al. showed that RHAMM can compensate for the
loss of CD44 in binding HA, thereby supporting migration in a
model of collagen-induced arthritis [38]. The observed compen-
sation in the above mentioned model was not due to an increase in
RHAMM expression, but rather by enhanced HA-induced
signaling through RHAMM. The potential role of RHAMM in
our OS model will be subject of a future detailed study.
In conclusion, the findings of our study imply that CD44 is a
negative regulator of metastasis in 143-B OS cells. The apparent
discrepancy between in vitro and in vivo outcomes of CD44 knock-
down on tumorigenic and metastatic properties of 143-B cells
highlights the essential impact of the tumor environment on OS
progression. CD44 functions as a metastasis suppressor gene in this
particular experimental OS. Although the 143-B cells were
representative for the expression pattern of CD44 gene products
observed in other cell lines, the here observed effects of CD44
silencing might be particularly important in OS cells with up-
regulated Ras activity. Future studies investigating CD44 expres-
sion in large cohorts of human tumor tissue samples will further
contribute to the delineation of its role in OS.
Supporting Information
Figure S1 Cell cycle analysis of 143-B EV, 143-B Ctrl
shRNA or 143-B shCD44 cells. Cell cycle progression was
measured by propidium iodide (PI) staining using flow cytometry.
Briefly, cells were trypsinized, washed once with cold PBS and
resuspended in 300 ml of cold PBS. Subsequently, cells were fixed
in ice cold ethanol and stored at 220uC overnight. The next day,
DNA was stained in PI/RNase staining buffer (BD Pharmingen
AG, Allschwil, Switzerland) at 37uC for 30 min in the dark. The
samples were analysed on a FACS machine (Calibur, BD) and the
cell cycle distribution was calculated using FlowJo software. The
values indicate the mean 6 SEM of six analyses from two
independent samples.
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